A business in context
TVTX research notebook
Read the disclosures. Follow the relationships. Keep the dates in view.
Filing timeline
Download filings CSVReported insider transactions
Download transactions CSVP · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
| Transaction / filed | Reporting owner | Type | Security | Shares | Reported price |
|---|---|---|---|---|---|
| 2026-06-22 | Inrig Jula | G · Gift | Common Stock | 468.0 | 0.0 |
| 2026-06-12 | Baynes Roy D. | S · Sale | Common Stock | 4500.0 | 50.0 |
| 2026-06-12 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 4500.0 | 21.38 |
| 2026-06-12 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 4500.0 | 0.0 |
| 2026-06-12 | Coughlin Timothy | M · Exercise / conversion | Common Stock | 10000.0 | 26.52 |
| 2026-06-12 | Coughlin Timothy | S · Sale | Common Stock | 10000.0 | 50.07 |
| 2026-06-12 | Coughlin Timothy | M · Exercise / conversion | Stock Option (Right to Buy) | 10000.0 | 0.0 |
| 2026-05-19 | Baynes Roy D. | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Baynes Roy D. | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | Poole Sandra | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Poole Sandra | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | Bruhn Suzanne Louise | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Bruhn Suzanne Louise | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | Meckler Jeffrey A | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Meckler Jeffrey A | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | Orwin John A | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Orwin John A | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | Squarer Ron | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Squarer Ron | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | Coughlin Timothy | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Coughlin Timothy | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | Williams Brinkley Ruth | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | Williams Brinkley Ruth | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-19 | LYONS GARY A | A · Grant / award | Common Stock | 4000.0 | 0.0 |
| 2026-05-19 | LYONS GARY A | A · Grant / award | Stock option (right to buy) | 12000.0 | 0.0 |
| 2026-05-15 | Coughlin Timothy | S · Sale | Common Stock | 3250.0 | 43.49 |
| 2026-05-06 | Cline Christopher R. | S · Sale | Common Stock | 310.0 | 43.95 |
| 2026-05-06 | Inrig Jula | S · Sale | Common Stock | 311.0 | 43.95 |
| 2026-05-06 | Dube Eric M | S · Sale | Common Stock | 22500.0 | 43.95 |
| 2026-05-06 | ROTE WILLIAM E. | S · Sale | Common Stock | 2763.0 | 43.95 |
| 2026-05-06 | REED ELIZABETH E | S · Sale | Common Stock | 2076.0 | 43.95 |
| 2026-05-05 | Cline Christopher R. | S · Sale | Common Stock | 2181.0 | 46.65 |
| 2026-05-05 | Inrig Jula | S · Sale | Common Stock | 2174.0 | 46.65 |
| 2026-05-05 | Heerma Peter | S · Sale | Common Stock | 2174.0 | 46.65 |
| 2026-05-05 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 4500.0 | 18.27 |
| 2026-05-05 | Baynes Roy D. | S · Sale | Common Stock | 4500.0 | 46.65 |
| 2026-05-05 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 4500.0 | 0.0 |
| 2026-05-05 | REED ELIZABETH E | S · Sale | Common Stock | 2174.0 | 46.65 |
| 2026-05-04 | Cline Christopher R. | M · Exercise / conversion | Common Stock | 4250.0 | 0.0 |
| 2026-05-04 | Cline Christopher R. | A · Grant / award | Performance-based restricted stock units | 8500.0 | 0.0 |
| 2026-05-04 | Cline Christopher R. | M · Exercise / conversion | Performance-based restricted stock units | 4250.0 | 0.0 |
| 2026-05-04 | Inrig Jula | M · Exercise / conversion | Common Stock | 4250.0 | 0.0 |
| 2026-05-04 | Inrig Jula | M · Exercise / conversion | Common Stock | 20000.0 | 22.4 |
| 2026-05-04 | Inrig Jula | S · Sale | Common Stock | 20000.0 | 45.0 |
| 2026-05-04 | Inrig Jula | M · Exercise / conversion | Employee stock option (right to buy) | 20000.0 | 0.0 |
| 2026-05-04 | Inrig Jula | M · Exercise / conversion | Performance-based restricted stock units | 4250.0 | 0.0 |
| 2026-05-04 | Inrig Jula | A · Grant / award | Performance-based restricted stock units | 8500.0 | 0.0 |
| 2026-05-04 | Heerma Peter | M · Exercise / conversion | Common Stock | 4250.0 | 0.0 |
| 2026-05-04 | Heerma Peter | A · Grant / award | Performance-based restricted stock units | 8500.0 | 0.0 |
| 2026-05-04 | Heerma Peter | M · Exercise / conversion | Performance-based restricted stock units | 4250.0 | 0.0 |
Identity & relationships
SEC issuer · 0001438533Travere Therapeutics, Inc.
Search names and former names
- Retrophin, Inc. · former SEC name · 2013-02-21 to 2020-11-13
- Desert Gateway, Inc. · former SEC name · 2008-06-27 to 2013-02-19
Revenue in constant purchasing power
| Year ended | Reported USD revenue | CPI-adjusted USD revenue |
|---|---|---|
| 2024-12-31 | $233.18M | $248.21M |
| 2023-12-31 | $145.24M | $159.15M |
| 2022-12-31 | $109.46M | $124.87M |
| 2021-12-31 | $131.84M | $162.43M |
| 2020-12-31 | $198.32M | $255.87M |
| 2019-12-31 | $175.34M | $229.00M |
| 2018-12-31 | $164.25M | $218.40M |
| 2017-12-31 | $154.94M | $211.06M |